Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9218363 | 1.00 | FAAH (0.44) | FAAHMAPTCA1CA2ACHE | |
| SCHEMBL25554148 | 0.94 | MTNR1A (0.44) | FAAHMAPTCA1CA2ACHE | |
| SCHEMBL5859196 | 0.87 | KMT2A (0.48) | MAPTACHEALDH1A1KMT2AKDM4E | |
| SCHEMBL344552 | 0.85 | CA1 (0.53) | FAAHCA1CA2ACHE | |
| SCHEMBL24214577 | 0.84 | FAAH (0.43) | FAAHMAPTCA1CA2ACHE | |
| SCHEMBL17443397 | 0.84 | HTR1D (0.48) | FAAHCA1CA2ACHEALDH1A1 | |
| SCHEMBL8076218 | 0.84 | CA1 (0.59) | FAAHCA1CA2ACHEMTNR1A | |
| SCHEMBL8066286 | 0.84 | CA1 (0.59) | FAAHCA1CA2ACHEMTNR1A | |
| SCHEMBL15431081 | 0.84 | FAAH (0.43) | FAAHCA1CA2ACHEKMT2A | |
| SCHEMBL8603697 | 0.84 | CA1 (0.59) | FAAHCA1CA2ACHEMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041703-B2 | 2-aminotetralines and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-05-09 | — | — | US | disclosed |
| US-6849663-B2 | 2-Aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2005-02-01 | — | — | US | disclosed |
| US-20030229148-A1 | 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. | 2003-12-11 | — | — | US | disclosed |
| EP-1017667-B1 | 2-Amino-6-methyl-7-acetyl-tetraline and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | SIGMA TAU IND FARMACEUTI (IT) | 2003-11-19 | — | — | EP | disclosed |
| US-20030158266-A1 | 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. | 2003-08-21 | — | — | US | disclosed |
| US-20020123652-A1 | 2-AMINOTETRALINES AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY AND/OR AUTOIMMUNE PATHOLOGIES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A (IT) | 2002-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123652-A1 | 2-AMINOTETRALINES AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY AND/OR AUTOIMMUNE PATHOLOGIES | AADAT, IL2, TPMT | FAAH 2462/4885MAPT 692/4885CA1 2326/4885 |
| US-20030229148-A1 | 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | AADAT, IL2, TPMT | FAAH 2784/4885MAPT 590/4885CA1 3043/4885 |
| US-20030158266-A1 | 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies | AADAT, IL2, TPMT | FAAH 2784/4885MAPT 590/4885CA1 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.